Last reviewed · How we verify
PET with 11C-Flumazenil
At a glance
| Generic name | PET with 11C-Flumazenil |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- PET with [18F]Flumazenil As an Index of Neurodegeneration in MS (NA)
- Characterization of [11C]Flumazenil to Image GABA Transmission in Healthy Adult Subjects and Subjects With Alcohol Dependence (PHASE1)
- Prognosis Value of the Neuronal Damage in Early Multiple Sclerosis (NA)
- Study of GABA-A Receptors in the Generation of Tics in Patients With Tourette's Syndrome
- Brain Changes in Patients With Focal Hand Dystonia
- A Study to Examine the Distribution of PF-06372865 in the Brain of Healthy Volunteers Using Positron Emission Tomography and a Radioactive Tracer Following Oral Administration of One Dose of PF-06372865 (PHASE1)
- Positron Emission Tomography (PET) Study With (11C) Flumazenil to Determine Central GABAA Receptor Occupancy of AZD6280 (PHASE1)
- Positron Emission Tomography (PET) Study With (11C)Flumazenil to Determine Central GABAA Receptor Occupancy of AZD7325 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PET with 11C-Flumazenil CI brief — competitive landscape report
- PET with 11C-Flumazenil updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI